The U.S. Food and Drug Administration has approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea, according to an FDA news release.
The safety and efficacy of Dificid were demonstrated in two trials that included 564 patients with CDAD that compared Dificid with vancomycin, a common antibiotic used to treat CDAD. The clinical response was similar in the Dificid group compared with the vancomycin group in both studies. In some patients with CDAD, symptoms can return. In the trials, a greater number of patients treated with Dificid had a sustained cure three weeks after treatment ended compared with patients treated with vancomycin.
Dificid was developed by San Diego-based Optimer Pharmaceuticals.
Read the FDA news release about Dificid.
Related Articles on C. Difficile:
10 Steps for Preventing C. Diff Outbreaks
C. Diff Increases Risk of Death 6-Fold in Inflammatory Bowel Disease Patients
6 Patients at New York Hospital Have C. Diff
The safety and efficacy of Dificid were demonstrated in two trials that included 564 patients with CDAD that compared Dificid with vancomycin, a common antibiotic used to treat CDAD. The clinical response was similar in the Dificid group compared with the vancomycin group in both studies. In some patients with CDAD, symptoms can return. In the trials, a greater number of patients treated with Dificid had a sustained cure three weeks after treatment ended compared with patients treated with vancomycin.
Dificid was developed by San Diego-based Optimer Pharmaceuticals.
Read the FDA news release about Dificid.
Related Articles on C. Difficile:
10 Steps for Preventing C. Diff Outbreaks
C. Diff Increases Risk of Death 6-Fold in Inflammatory Bowel Disease Patients
6 Patients at New York Hospital Have C. Diff
